Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
- PMID: 9559817
- PMCID: PMC105576
- DOI: 10.1128/AAC.42.4.947
Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
Abstract
Oxazolidinone-resistant mutants of Staphylococcus aureus, isolated with a spiral plating technique, had a 16-fold higher MIC (2 versus 32 microg/ml) of eperezolid when compared to the parental sensitive strain. Eperezolid inhibited in vitro protein translation with 50% inhibitory concentrations of 30 microM for the oxazolidinone-sensitive S30 extract and 75 microM for the resistant extract. Experiments mixing various combinations of S100 and crude ribosome preparations from oxazolidinone-sensitive and -resistant S. aureus strains in a transcription-translation assay demonstrated that the resistant determinant resided within the ribosomal fraction. Ribosomes from the oxazolidinone-resistant strain bound less drug than ribosomes from the sensitive strain, indicating that the ribosome is the site of action for the oxazolidinones. These experiments demonstrate that an alteration of the ribosome is responsible for some or all of the oxazolidinone resistance observed in the S. aureus mutant.
Figures



Similar articles
-
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6. doi: 10.1128/AAC.41.10.2132. Antimicrob Agents Chemother. 1997. PMID: 9333037 Free PMC article.
-
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721. Antimicrob Agents Chemother. 1998. PMID: 9517963 Free PMC article.
-
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.Antimicrob Agents Chemother. 2008 Oct;52(10):3550-7. doi: 10.1128/AAC.01193-07. Epub 2008 Jul 28. Antimicrob Agents Chemother. 2008. PMID: 18663023 Free PMC article.
-
Oxazolidinone antibacterial agents: a critical review.Curr Top Med Chem. 2003;3(9):1021-42. doi: 10.2174/1568026033452195. Curr Top Med Chem. 2003. PMID: 12678835 Review.
-
Tedizolid for the management of human infections: in vitro characteristics.Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Clin Infect Dis. 2014. PMID: 24343830 Review.
Cited by
-
Oxazolidinones: a review.Drugs. 2000 Jan;59(1):7-16. doi: 10.2165/00003495-200059010-00002. Drugs. 2000. PMID: 10718097 Review.
-
Ribosomal alterations contribute to bacterial resistance against the dipeptide antibiotic TAN 1057.Antimicrob Agents Chemother. 2004 Feb;48(2):619-22. doi: 10.1128/AAC.48.2.619-622.2004. Antimicrob Agents Chemother. 2004. PMID: 14742220 Free PMC article.
-
The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.Antimicrob Agents Chemother. 1998 Dec;42(12):3251-5. doi: 10.1128/AAC.42.12.3251. Antimicrob Agents Chemother. 1998. PMID: 9835522 Free PMC article.
-
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?Can J Infect Dis. 2001 Nov;12(6):379-90. doi: 10.1155/2001/260651. Can J Infect Dis. 2001. PMID: 18159365 Free PMC article.
References
-
- Barbachyn M R, Hutchinson D K, Brickner S J, Cynamon M H, Kilburn O J, Klemens S P, Glickman S E, Grega K C, Hendges S K, Toops D S, Ford C W, Zurenko G E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39:680–685. - PubMed
-
- Brickner S J, Hutchinson D K, Barbachyn M R, Manninen P R, Ulanowicz D A, Garmon S A, Grega K C, Hendges S K, Toops D S, Ford C W, Zurenko G E. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39:673–679. - PubMed
-
- Brumfitt W, Hamilton-Miller J M T. Antibacterial oxazolidinones: in vitro activity of a new analogue, E3709. Diagn Microbiol Infect Dis. 1992;15:621–625. - PubMed
-
- Daly J S, Eliopoulos G M, Reiszner E, Moellering R C. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. Antimicrob Agents Chemother. 1988;21:721–730. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical